Jazz Pharmaceuticals Reports Record 2025 Revenue, Driven by Xywav Growth
The low-sodium oxybate oral solution generated $1.7 billion in revenue, contributing to the company's $3.1 billion neuroscience portfolio performance in 2025.
The low-sodium oxybate oral solution generated $1.7 billion in revenue, contributing to the company's $3.1 billion neuroscience portfolio performance in 2025.
In the third quarter, low-sodium Xywav grew 30% year-over-year, despite additional competition, with continued adoption across both narcolepsy and idiopathic hypersomnia
Tris has developed an oxybate formulation intended for the treatment of cataplexy or excessive daytime sleepiness in people with narcolepsy.
Read MoreOn February 9, Jazz Pharmaceuticals plc made changes to its XYWAV and XYREM prescription forms to decrease prescriber confusion.
Read MoreThe FDA also published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness associated with narcolepsy.
Read MoreA literature review from Stanford University looks at how the popular narcolepsy medication sodium oxybate impacts heart health.
Read MoreThe FDA approved a new oxybate formulation for excessive daytime sleepiness or cataplexy in narcolepsy. Should your patients switch?
Read MoreHighlights include presentations on Xywav, a lower sodium oxybate iindicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Read MoreMarketed by Jazz Pharmaceuticals, Xywav is for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read MoreThe FDA accepted for filing with Priority Review the Jazz Pharmaceuticals plc’s NDA seeking marketing approval for JZP-258, an investigational medicine for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Read MoreSolriamfetol, which will be branded as Sunosi, has been backed for the treatment of excessive sleepiness in adult patients with narcolepsy and obstructive sleep apnea (OSA), according to a statement from the...
Read More